In Vitro and In Vivo Activities of LCB01-0371, a New Oxazolidinone

• DOI: 10.1128/aac.00723-10
• Publication Date: 2010-09-21T04:51:28Z
• Authors: Ji-Woong Jeong; Sung-Ji Jung; Hyun-Hee Lee; Yong-Zu Kim; Tae-Kyo Park; Young-Lag Cho; Sang-Eun Chae; Sung-Yoon Baek; Sung-Ho Woo; Hyang-Sook Lee; Jin-Hwan Kwak
• Keywords: Male; 0301 basic medicine; Mice, Inbred ICR; Staphylococcus aureus; 0303 health sciences; Linezolid; Bacterial Infections; Gram-Positive Bacteria; Anti-Bacterial Agents; 3. Good health; Mice; 03 medical and health sciences; Vancomycin; Acetamides; Animals; Oxazolidinones

ABSTRACT

LCB01-0371 is a new oxazolidinone with cyclic amidrazone. In vitro activity of LCB01-0371 against 624 clinical isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics. LCB01-0371 showed good activity against Gram-positive pathogens. In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated. LCB01-0371 was more active than linezolid against these systemic infections. LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.